The purpose of this study was to determine whether sulglycotide (Gliptide), an extractive molecule, would prevent the onset of upper gastro-intestinal mucosal lesions in patients with rheumatic disease treated with non-steroidal anti-inflammatory drugs (NSAIDs). The study was conducted on a completely randomized, double-blind experimental design v. placebo. The trial involved a total of 131 ambulatory patients with extant rheumatoid arthritis (RA) or osteo-arthrosis (OA), free of endoscopically detectable lesions of gastroduodenal mucosa and being treated with piroxicam, diclofenac, naproxen, or indomethacin. Along with their NSAID medication, the patients were given sulglycotide 200 mg t.i.d. or an indistinguishable placebo for a period of eight weeks. At the end of the study, each patient was re-checked for clinical symptoms and endoscopy findings. The overall incidence of lesions of the gastric mucosa was 8.9% in the group treated with sulglycotide as opposed to 32.8% in the placebo...
EFFECTIVENESS OF SULGLYCOTIDE (GLIPTIDE) IN PREVENTION OF GASTRIC-LESIONS FROM NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN PATIENTS WITH RHEUMATIC DISEASE - A CONTROLLED DOUBLE-BLIND ENDOSCOPIC STUDY V PLACEBO
TROTTA, Francesco;
1990
Abstract
The purpose of this study was to determine whether sulglycotide (Gliptide), an extractive molecule, would prevent the onset of upper gastro-intestinal mucosal lesions in patients with rheumatic disease treated with non-steroidal anti-inflammatory drugs (NSAIDs). The study was conducted on a completely randomized, double-blind experimental design v. placebo. The trial involved a total of 131 ambulatory patients with extant rheumatoid arthritis (RA) or osteo-arthrosis (OA), free of endoscopically detectable lesions of gastroduodenal mucosa and being treated with piroxicam, diclofenac, naproxen, or indomethacin. Along with their NSAID medication, the patients were given sulglycotide 200 mg t.i.d. or an indistinguishable placebo for a period of eight weeks. At the end of the study, each patient was re-checked for clinical symptoms and endoscopy findings. The overall incidence of lesions of the gastric mucosa was 8.9% in the group treated with sulglycotide as opposed to 32.8% in the placebo...I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
